V. Valero

1.1k total citations
33 papers, 708 citations indexed

About

V. Valero is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, V. Valero has authored 33 papers receiving a total of 708 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 15 papers in Cancer Research and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in V. Valero's work include Breast Cancer Treatment Studies (12 papers), Cancer Treatment and Pharmacology (9 papers) and Advanced Breast Cancer Therapies (8 papers). V. Valero is often cited by papers focused on Breast Cancer Treatment Studies (12 papers), Cancer Treatment and Pharmacology (9 papers) and Advanced Breast Cancer Therapies (8 papers). V. Valero collaborates with scholars based in United States, United Kingdom and Japan. V. Valero's co-authors include Gabriel N. Hortobágyi, Aman U. Buzdar, Banu Arun, Shu‐Wan Kau, Kristine Broglio, Daniel J. Booser, Melissa L. Bondy, Francisco J. Esteva, Cesar A. Santa‐Maria and Abenaa M. Brewster and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

V. Valero

32 papers receiving 695 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
V. Valero United States	11	456	339	177	152	116	33	708
Marzena Wełnicka-Jaśkiewicz Poland	17	610 1.3×	354 1.0×	154 0.9×	165 1.1×	85 0.7×	42	820
Budhi Singh Yadav India	13	240 0.5×	272 0.8×	146 0.8×	133 0.9×	125 1.1×	85	666
J. Lindtner Switzerland	11	471 1.0×	302 0.9×	131 0.7×	223 1.5×	93 0.8×	12	679
Winfried Schoenegg Germany	13	354 0.8×	242 0.7×	194 1.1×	206 1.4×	54 0.5×	24	636
Florence Coussy France	15	393 0.9×	295 0.9×	139 0.8×	185 1.2×	99 0.9×	59	734
Gary Unzeitig United States	12	542 1.2×	524 1.5×	163 0.9×	165 1.1×	152 1.3×	28	855
Michaela L. Tsai United States	17	561 1.2×	244 0.7×	200 1.1×	101 0.7×	124 1.1×	35	850
Sara López‐Tarruella Spain	19	672 1.5×	277 0.8×	240 1.4×	228 1.5×	49 0.4×	89	962
Laura Adamoli Italy	20	897 2.0×	566 1.7×	316 1.8×	162 1.1×	56 0.5×	42	1.2k
Sheryl L. Parker United States	6	425 0.9×	302 0.9×	101 0.6×	122 0.8×	180 1.6×	7	659

Countries citing papers authored by V. Valero

Since Specialization

Citations

This map shows the geographic impact of V. Valero's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V. Valero with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V. Valero more than expected).

Fields of papers citing papers by V. Valero

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V. Valero. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V. Valero. The network helps show where V. Valero may publish in the future.

Co-authorship network of co-authors of V. Valero

This figure shows the co-authorship network connecting the top 25 collaborators of V. Valero. A scholar is included among the top collaborators of V. Valero based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with V. Valero. V. Valero is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Huang, C-Y, Lilja B. Sólnes, Vandana G. Abramson, et al.. (2022). 191P Correlation of early change in standardized uptake value (SUV) on positron emission tomography (PET/CT) with recurrence-free survival (RFS) and overall survival (OS) in patients with primary operable HER2-positive breast cancer (TBCRC026). Annals of Oncology. 33. S623–S624. 1 indexed citations

Tolcher, Anthony W., Razelle Kurzrock, V. Valero, et al.. (2020). Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors. Cancer Chemotherapy and Pharmacology. 85(4). 673–683. 47 indexed citations

Damodaran, Senthil, Funda Meric‐Bernstam, JK Litton, et al.. (2019). Abstract OT1-03-04: INTERACT- INTegrated Evaluation of Resistance and Actionability using Circulating Tumor DNA in hormone receptor (HR) positive metastatic breast cancers (MBC). Cancer Research. 79(4_Supplement). OT1–3. 1 indexed citations

Lim, Bora, Summer Jackson, Abenaa M. Brewster, et al.. (2016). Abstract P4-14-22: A single-center, open-label phase 1b study of entinostat, and lapatinib alone, and in combination with and trastuzumab in patients with HER2+ metastatic breast cancer after progression on trastuzumab. Cancer Research. 76(4_Supplement). P4–14. 1 indexed citations

Ratcliff, Chelsea G., Cho Y. Lam, Banu Arun, V. Valero, & Lorenzo Cohen. (2014). Ecological momentary assessment of sleep, symptoms, and mood during chemotherapy for breast cancer. Psycho-Oncology. 23(11). 1220–1228. 33 indexed citations

Iwamoto, Takashi, V. Valero, Karen L. Koenig, et al.. (2011). P1-07-09: Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1%-10% ER-Positive by Immunohistochemistry.. Cancer Research. 71(24_Supplement). P1–7.

Giordano, Antonio, Simone Anfossi, Catherine Parker, et al.. (2011). Epithelial-mesenchymal transition in patients with HER2+ metastatic breast cancer.. Journal of Clinical Oncology. 29(15_suppl). 623–623. 5 indexed citations

Giordano, Antonio, Mario Giuliano, Li‐Han Hsu, et al.. (2010). Prognostic value of circulating tumor cells (CTC) in metastatic breast cancer (MBC): Correlation with immunohistochemically defined molecular subtypes and metastatic disease sites.. Journal of Clinical Oncology. 28(15_suppl). 1000–1000. 8 indexed citations

Giorgi, Ugo De, V. Valero, Eric Rohren, et al.. (2009). Circulating tumor cells and bone metastases as detected by FDG–PET/CT in patients with metastatic breast cancer. Annals of Oncology. 21(1). 33–39. 74 indexed citations

10.

Cristofanilli, Massimo, Rachel Schiff, V. Valero, et al.. (2009). Exploratory subset analysis according to prior endocrine treatment of two randomized phase II trials comparing gefitinib (G) with placebo (P) in combination with tamoxifen (T) or anastrozole (A) in hormone receptor-positive (HR+) metastatic breast cancer (MBC). Journal of Clinical Oncology. 27(15_suppl). 1014–1014. 10 indexed citations

11.

Cristofanilli, Massimo, Eric Rohren, Naoto T. Ueno, et al.. (2009). Circulating tumor cells and FDG-PET/CT: biological and functional methods for therapeutic monitoring in metastatic breast cancer.. Cancer Research. 69(2_Supplement). 6052–6052. 1 indexed citations

12.

Broglio, Kristine, Fátima Cardoso, JK Litton, et al.. (2009). Significant increased recurrence rates among breast cancer patients with HER2-positive, T1a,bN0M0 tumors.. Cancer Research. 69(2_Supplement). 701–701. 14 indexed citations

13.

Markman, B., et al.. (2008). Pharmacodynamic (PD) endpoints and cellular proliferation effects of NVP-BEZ235, a dual PI3K/mTOR inhibitor, in breast cancer cells and xenografts with wild-type (WT) and activating PI3K mutations. Journal of Clinical Oncology. 26(15_suppl). 14508–14508. 1 indexed citations

14.

Symmans, W. Fraser, Christos Hatzis, C Liedtke, et al.. (2008). Use of genomic grade index (GGI) to predict pathologic response to preoperative chemotherapy in breast cancer. Journal of Clinical Oncology. 26(15_suppl). 541–541. 2 indexed citations

15.

Cristofanilli, Massimo, V. Valero, A Mangalik, et al.. (2008). A phase II multicenter, double-blind, randomized trial to compare anastrozole plus gefinitib with anastrozole plus placebo in postmenopausal women with hormone receptor-positive (HR+) metastatic breast cancer (MBC). Journal of Clinical Oncology. 26(15_suppl). 1012–1012. 39 indexed citations

16.

Amin, Sapna, et al.. (2006). Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel. Journal of Clinical Oncology. 24(18_suppl). 659–659. 4 indexed citations

17.

Cristofanilli, Massimo, Valentina Guarneri, V. Valero, et al.. (2006). Circulating tumor cells (CTCs) in metastatic breast cancer: Biological value beyond tumor burden. Journal of Clinical Oncology. 24(18_suppl). 615–615. 1 indexed citations

18.

Symmans, W. Fraser, Florentia Peintinger, Christos Hatzis, et al.. (2006). A new measurement of residual cancer burden to predict survival after neoadjuvant chemotherapy. Journal of Clinical Oncology. 24(18_suppl). 536–536. 6 indexed citations

19.

Chagpar, Anees B., Lavinia P. Middleton, Ayşegül A. Şahin, et al.. (2005). Clinical outcome of patients with lymph node‐negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer. 103(8). 1581–1586. 77 indexed citations

20.

Valero, V., Zaid Abdel Rahman, D. Frye, et al.. (1998). Clinical course of breast cancer patients with metastases confined to the lungs treated with chemotherapy. Annals of Oncology. 9(4). 413–418. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact